FGFR3 Y373C is a transmembrane-domain activating mutation in urothelial carcinoma; includ...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-FGFR3-Y373C-UROTHELIAL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-UROTHELIAL |
| Sources | SRC-CIVIC SRC-EAU-BLADDER-2024 SRC-NCCN-BLADDER-2025 |
Actionability Facts
| Biomarker | BIO-FGFR3-MUTATION |
|---|---|
| Variant | Y373C |
| Disease | DIS-UROTHELIAL |
| ESCAT tier | IA |
| Recommended combinations | erdafitinib monotherapy |
| Evidence summary | FGFR3 Y373C is a transmembrane-domain activating mutation in urothelial carcinoma; included in erdafitinib companion-diagnostic panel. Treatment identical to other actionable FGFR3 mutations: erdafitinib 2L+ post-platinum. |
Notes
ESCAT IA. Companion diagnostic panel positive.
Used By
No reverse references found in the YAML corpus.